中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

73 records (took 0.031 seconds)

    OCULAR NANOFORMULATION AND METHOD OF USE IN ANGIOGENESIS-MEDIATED DISORDERS
    31.
    发明申请
    OCULAR NANOFORMULATION AND METHOD OF USE IN ANGIOGENESIS-MEDIATED DISORDERS 审中-公开
    血管生成介导的疾病中的OCULAR NANOFORMULATION和使用方法

    公开(公告)号：US20150140106A1

    公开(公告)日：2015-05-21

    申请号：US14526738

    申请日：2014-10-29

    Applicant: Shaker A. Mousa

    Inventor： Shaker A. Mousa

    IPC: A61K9/50 ,  A61K45/06 ,  A61K47/48 ,  A61K31/727 ,  A61K9/00

    CPC classification number: A61K9/5036 ,  A61K9/0048 ,  A61K9/5026 ,  A61K9/5146 ,  A61K9/5153 ,  A61K9/5161 ,  A61K31/727 ,  A61K45/06 ,  A61K47/6933

    Abstract: An ophthalmic formulation that includes nanoparticles. Each nanoparticle includes a shell which encapsulates sulfated non-anticoagulant heparin (SNACH), with or without hydrophobic anti-angiogenesis Tyrosine Kinase inhibitors. The SNACH is ionically or covalently bonded to the shell. The shell includes a polymer selected from the group consisting of poly (lactic-co-glycolic acid) (PLGA), chitosan, chitosan-alginate, and NIPAAM-APMAH-AA, wherein NIPAAM is N-isopropyl acrylamide, APMAH is N-3-aminopropylmethacrylamide hydrochloride, and AA is acrylic acid. A method for treating an eye disease of a subject includes: administering to an eye of the subject a therapeutically effective amount of the ophthalmic formulation for treating the eye disease. The eye disease involves an ocular angiogenesis-mediated disorder.

    Abstract translation: 包括纳米颗粒的眼用制剂。 每个纳米颗粒包括封装硫酸化非抗凝血剂肝素（SNACH）的壳，具有或不具有疏水性抗血管生成酪氨酸激酶抑制剂。 SNACH离子或共价键合到壳上。 壳包括选自聚（乳酸 - 共 - 乙醇酸）（PLGA），壳聚糖，壳聚糖 - 藻酸盐和NIPAAM-APMAH-AA的聚合物，其中NIPAAM是N-异丙基丙烯酰胺，APMAH是N-3 氨基丙基甲基丙烯酰胺盐酸盐，AA是丙烯酸。 用于治疗受试者的眼睛疾病的方法包括：向患者的眼睛施用治疗有效量的用于治疗眼睛疾病的眼用制剂。 眼病涉及眼血管生成介导的病症。

    Formulations of factor VIIa inhibitors and utility
    33.
    发明授权
    Formulations of factor VIIa inhibitors and utility 有权
    因子VIIa抑制剂和效用的制剂

    公开(公告)号：US08481479B1

    公开(公告)日：2013-07-09

    申请号：US13414106

    申请日：2012-03-07

    Applicant: Shaker A. Mousa

    Inventor： Shaker A. Mousa

    IPC: A61K38/00 ,  A61K38/05 ,  C07K14/755

    CPC classification number: A61K38/4846 ,  A61K9/1273 ,  A61K9/19 ,  A61K9/5146 ,  A61K47/6935 ,  A61K47/6939 ,  C12N9/6437

    Abstract: A nanoparticle, a chemical structure, and a treatment method for treating a patient having a disorder. The nanoparticle includes a poly L-arginine polymer and a Factor VIIa inhibitor conjugated to or encapsulated in the poly L-arginine polymer. The chemical structure includes a Factor VIIa inhibitor that includes at least one nitric oxide (NO) donor. The treatment method administers a therapeutic effective amount of the nanoparticle or chemical structure to the patient to treat the disorder. The disorder may be a vascular disorder, pulmonary hypertension, cardiac insufficiency, a neurological disorder, and combinations thereof.

    Abstract translation: 纳米颗粒，化学结构和用于治疗患有病症的患者的治疗方法。 纳米颗粒包括聚L-精氨酸聚合物和与聚L-精氨酸聚合物缀合或包封的因子VIIa抑制因子。 该化学结构包括包含至少一种一氧化氮（NO）供体的因子VIIa抑制剂。 治疗方法向患者施用治疗有效量的纳米颗粒或化学结构以治疗该病症。 该病症可以是血管疾病，肺动脉高压，心功能不全，神经障碍及其组合。

    NANOFORMULATION OF VITAMIN D DERIVATIVES AND/OR VITAMIN D METABOLITES
    34.
    发明申请
    NANOFORMULATION OF VITAMIN D DERIVATIVES AND/OR VITAMIN D METABOLITES 有权
    维生素D衍生物和/或维生素D代谢物的纳米制剂

    公开(公告)号：US20130149385A1

    公开(公告)日：2013-06-13

    申请号：US13706755

    申请日：2012-12-06

    Applicant: Shaker A. Mousa

    Inventor： Shaker A. Mousa

    IPC: A61K9/51

    CPC classification number: A61K9/5161 ,  A61K47/48038 ,  A61K47/4823 ,  A61K47/542 ,  A61K47/61 ,  B82Y5/00 ,  Y10S977/773 ,  Y10S977/906

    Abstract: A nanoformulation that includes loaded nanoparticles. Each nanoparticle includes a modified chitosan polymer encapsulating at least one vitamin D derivative, at least one vitamin D metabolite, or combinations thereof. The modified chitosan polymer includes chitosan covalently linked to at least one entity selected from the group consisting of fatty acids (omega-3-fattay acids), amino acids, deoxycholic acid, alginate, arginine-alginate, hyaluronic acid, collagen, collagen-hydroxyapatite, poly(lactic-co-glycolic acid) (PLGA), and combinations thereof. A structure includes a medium and the nanoformulation, wherein the nanoparticles are dispersed in the medium. A method of using the nanoformulation to treat a disorder and improve efficacy of current therapies where resistance develop in a patient includes administering to the patient a therapeutically effective amount of the nanoformulation for treating the disorder. A nano-cosmetic formulation, comprising a cosmetic includes the nanoformulation, wherein the modified chitosan polymer encapsulates the at least one vitamin D derivative, and wherein the at least one vitamin D derivative encompasses 0.1 to 20.0 wt % of the nano-cosmetic formulation's total weight.

    Abstract translation: 包括负载纳米粒子的纳米制剂。 每个纳米颗粒包括包封至少一种维生素D衍生物，至少一种维生素D代谢物或其组合的改性壳聚糖聚合物。 改性的壳聚糖聚合物包括共价连接到选自脂肪酸（ω-3-脂肪酸），氨基酸，脱氧胆酸，藻酸盐，精氨酸 - 藻酸盐，透明质酸，胶原，胶原 - 羟基磷灰石 ，聚（乳酸 - 共 - 乙醇酸）（PLGA）及其组合。 一种结构包括介质和纳米制剂，其中纳米颗粒分散在介质中。 使用纳米制剂治疗病症并改善当前治疗方法的功效的方法，其中患者的耐药性发展包括向患者施用治疗有效量的用于治疗病症的纳米制剂。 包含化妆品的纳米化妆品制剂包括纳米制剂，其中所述改性的壳聚糖聚合物包封所述至少一种维生素D衍生物，并且其中所述至少一种维生素D衍生物包含纳米化妆品制剂的总重量的0.1至20.0重量％ 。

    Method and system with contact lens product for treating and preventing adverse eye conditions
    35.
    发明授权
    Method and system with contact lens product for treating and preventing adverse eye conditions 有权
    用于治疗和预防不良眼睛状况的隐形眼镜产品的方法和系统

    公开(公告)号：US08440217B1

    公开(公告)日：2013-05-14

    申请号：US11153598

    申请日：2005-06-15

    Applicant: Mawaheb M. El-Naggar ,  Shaker A. Mousa

    Inventor： Mawaheb M. El-Naggar ,  Shaker A. Mousa

    IPC: A61F9/00 ,  A61F2/14 ,  B29D11/02 ,  G02B1/04

    CPC classification number: A61F9/0017 ,  B29D11/00096 ,  G02B1/043 ,  C08L83/04 ,  C08L101/14

    Abstract: A contact lens product, a method and system for forming the contact lens product, and a method of using the contact lens product. The contact lens product includes a soft disposable contact lens loaded with a drug and the carriers which carry the drug. The lens has a mechanical and optical structure formed by the core polymer included within the lens. The contact lens product is configured to have the drug released from its carrier continuously into an eye of a mammal while the contact lens product is adhered to the eye of the mammal during a continuous period of time, the drug being configured to treat or prevent at least one adverse condition of the eye of the mammal during the continuous period of time. The mammal may be a human being or a veterinary animal.

    Abstract translation: 隐形眼镜产品，用于形成隐形眼镜产品的方法和系统以及使用隐形眼镜产品的方法。 隐形眼镜产品包括装有药物的软的一次性隐形眼镜和携带药物的载体。 透镜具有由包含在透镜内的芯聚合物形成的机械和光学结构。 隐形眼镜产品被配置为使药物从其载体中连续地释放到哺乳动物的眼睛中，同时将隐形眼镜产品在连续的时间期间附着于哺乳动物的眼睛，该药物被配置为治疗或预防 持续时间内哺乳动物眼睛的至少一种不良状况。 哺乳动物可以是人类或兽医动物。

    OXIDIZED HEPARIN FRACTIONS AND THEIR USE IN INHIBITING ANGIOGENESIS
    36.
    发明申请
    OXIDIZED HEPARIN FRACTIONS AND THEIR USE IN INHIBITING ANGIOGENESIS 有权
    氧化HEPARIN分子及其在抑制血管生成中的应用

    公开(公告)号：US20110200673A1

    公开(公告)日：2011-08-18

    申请号：US13029584

    申请日：2011-02-17

    Applicant: Shaker A. Mousa

    Inventor： Shaker A. Mousa

    IPC: A61K9/14 ,  A61P7/02 ,  A61K31/727 ,  C08B37/10 ,  A61P35/00 ,  A61K9/00

    CPC classification number: A61K31/727 ,  A61K31/737 ,  A61K45/06 ,  C08B37/0078 ,  A61K2300/00

    Abstract: The present invention relates to a heparin fraction comprising constituents having molecular weights of from about 2,000 to about 4,000 daltons, wherein from about 1% to about 100% of hydroxyl residues of the constituents are oxidized. The present invention also relates to methods of inhibiting angiogenesis and treating an angiogenesis-mediated disorder in a subject by administering a heparin fraction comprising constituents having molecular weights of from about 2,000 to about 30,000 daltons, wherein from about 1% to about 100% of hydroxyl residues of the constituents are oxidized. Another aspect of the present invention relates to compositions including the heparin fractions of the present invention.

    Abstract translation: 本发明涉及包含分子量为约2,000至约4,000道尔顿的成分的肝素级分，其中约1％至约100％的组分的羟基残基被氧化。 本发明还涉及通过施用包含分子量为约2,000至约30,000道尔顿的组分的肝素级分，其中约1％至约100％的羟基，通过施用抑制血管发生并治疗受试者血管生成介导的病症的方法 组分的残基被氧化。 本发明的另一方面涉及包含本发明的肝素级分的组合物。

    NANO CO-ENCAPSULATION FOR THE PREVENTION AND TREATMENT OF VARIOUS DISORDERS
    40.
    发明申请
    NANO CO-ENCAPSULATION FOR THE PREVENTION AND TREATMENT OF VARIOUS DISORDERS 审中-公开
    NANO预防和治疗各种疾病的合并

    公开(公告)号：US20160338971A1

    公开(公告)日：2016-11-24

    申请号：US15011976

    申请日：2016-02-01

    Applicant: Shaker A. Mousa ,  Soad K. Jaouni

    Inventor： Shaker A. Mousa ,  Soad K. Jaouni

    IPC: A61K9/51 ,  A61K31/095 ,  A61K31/366 ,  A61K31/05 ,  A61K36/889

    CPC classification number: A61K9/5161 ,  A61K9/0019 ,  A61K9/0095 ,  A61K9/5123 ,  A61K9/5153 ,  A61K31/05 ,  A61K31/095 ,  A61K31/366 ,  A61K31/722 ,  A61K36/889 ,  A61K36/8962

    Abstract: A nano-composition that includes nanoparticles, a method of forming the nano-composition, and a method of using the composition. The nanoparticles include a nano-shell and one or more compounds co-encapsulated within the nano-shell. The nano-shell of each nanoparticle includes one or more chitosan polymers and one or more polymers subject to each chitosan polymer being covalently bonded to the one or more polymer. Each chitosan polymer in the nano-shell of each nanoparticle includes chitosan, tri-methylated chitosan, or a combination thereof. The one or more polymers in the nano-shell of each nanoparticle include poly (lactide-co-glycolide) (PLGA), one or more fatty acids, or combinations thereof subject to each fatty acid including oligomer epigallocatechin-3-gallate (OEGCG), hyaluronic acid, oleic acids, myristic acid, caprylic acid, or combinations thereof. Each compound co-encapsulated within the nano-shell includes ajwa extracts, pomegranate extracts, garlic extracts, one or more polyphenols, one or more thiols, or combinations thereof.

    Abstract translation: 包括纳米颗粒的纳米组合物，形成纳米组合物的方法和使用该组合物的方法。 纳米颗粒包括纳米壳和一个或多个共同包封在纳米壳内的化合物。 每个纳米颗粒的纳米壳包括一种或多种壳聚糖聚合物和一种或多种聚合物，其受到每种壳聚糖聚合物共价键合到一种或多种聚合物上。 每个纳米颗粒的纳米壳中的每个壳聚糖聚合物包括壳聚糖，三甲基化壳聚糖或其组合。 每个纳米颗粒的纳米壳中的一种或多种聚合物包括聚（丙交酯 - 共 - 乙交酯）（PLGA），一种或多种脂肪酸或其组合，其经受每种脂肪酸包括低聚表儿没食子儿茶素-3-没食子酸酯（OEGCG） ，透明质酸，油酸，肉豆蔻酸，辛酸或其组合。 共纳入纳米壳内的每种化合物包括水提取物，石榴提取物，大蒜提取物，一种或多种多酚，一种或多种硫醇或其组合。

Patent Agency Ranking